期刊文献+

艾司西酞普兰片联合氯硝西泮注射液治疗焦虑症的临床研究 被引量:9

Clinical research of Escitalopram Tablets combined with Clonazepam Injection in the treatment of anxiety disorders
下载PDF
导出
摘要 目的观察艾司西酞普兰片联合小剂量氯硝西泮注射液治疗焦虑症的疗效和不良反应。方法对65例符合标准的焦虑症患者分成两组,研究组33例给予艾司西酞普兰片联合氯硝西泮注射液静脉滴注,对照组32例仅用艾司西酞普兰片治疗,疗程为6周,采用汉密尔顿焦虑量表(HAMA)和不良反应量表(TESS)评定疗效和不良反应。结果两组总体疗效差异有统计学意义,氯硝西泮注射液组(研究组)抗焦虑显效更快;在第6周末,治愈率、临床显效率明显高于对照组;在整个治疗过程中,副反应没有明显增加。结论艾司西酞普兰片短期合并氯硝西泮注射液可以加快焦虑综合征缓解的速度,明显提高焦虑症的治疗效果,副反应没有明显增加,值得临床推广。 Objective To observe the curative effects and adverse reactions of Escitalopram Tablets combined with small dose of Clonazepam Injection in treatment of anxiety disorders. Methods Sixty-five patients met the criteria of anxiety disorders were randomly divided into research group and control group. In research group, 33 patients were given Escitalopram Tablets with Clonazepam Injection, while in control group, only Escitalopram Tablets were provid- ed. The curative effects and adverse reactions were evaluated by HAMA scale and TESS scale after 6 weeks treatment in both groups. Results There was significant difference in total curative effect. To be specific, effect of anti-anxiety in research group was faster than that in control group. At the end of sixth week, the cure rate and clinical effective rate were remarkably higher than those in control group. Throughout the treatment, the side reactions did not show great increase. Conclusion The Escitalopram Tablets combined with Clonazepam Injection in short-term can speed up the alleviation of anxiety disorders, significantly improve its curative effect, and there is no obvious increase in side reac- tions, it is worthy of clinical extension.
出处 《中国当代医药》 2013年第5期42-44,共3页 China Modern Medicine
关键词 艾司西酞普兰 焦虑症 氯硝西泮 HAMA Escitalopram Anxiety disorders Clonazepam HAMA
  • 相关文献

参考文献9

  • 1中华医学会精神科分会.中国精神障碍分类与诊断标准[M]济南:山东科学技术出版社,2001105-107.
  • 2张明圆.精神科评定量表手册[M]长沙:湖南科学技术出版社,1993134.
  • 3沈渔邨.精神病学[M]北京:人民卫生出版社,2008460.
  • 4Stein DJ,Berk M,Els C. A double blind placebo cont rolled trial of paroxetine in the management of social phobia(social anxiety disorder)[J].South Afrian SAfr Med,1999.402-406.
  • 5Wagner W,Labormy BA,Gray TE. Escitalopram:Areiew of its safety profile in worldwide studies[J].International Clinical Psycho pharmacology,1994.222.
  • 6张心保,刘玉成,林其根,马秋晖,张长岭,蔡则环.氯硝安定治疗焦虑症100例[J].江苏医药,1992,18(5):287-288. 被引量:1
  • 7汪春运.广泛性焦虑症的治疗进展[J].四川精神卫生,2011,24(4):250-254. 被引量:5
  • 8张旺信,李志刚,赵燕.氯丙咪嗪与丙咪嗪治疗广泛性焦虑症的随机对照研究[J].现代康复,2001,5(11):98-98. 被引量:1
  • 9陈彦方;顾牛范.新编临床精神科药物手册[M]济南:山东科学技术出版社,1998148-151.

二级参考文献13

  • 1沈渔村.精神病学(第3版)[M].北京:人民卫生出版社,1995.559-560,679.
  • 2Canadian Psychiatric Association. 7. Generalized Anxiety Disorder [ J]. Can J Psychiatry,2006,51 (Suppl 2) :51 - 56.
  • 3Pollack MH. Refractory generalized anxiety disorder[ J]. J Clin Psy- chiatry ,2009,70( Suppl 2 ) :32 - 38.
  • 4Davidson JR. First - line pharmacotherapy approaches for generalized anxiety disorder[ J ]. J Clin Psychiatry ,2009,70 ( Suppl 2 ) :25 - 31.
  • 5Simon NM. Generalized anxiety disorder and psychiatric comorbidities such as depression,bipolar disorder, and substance abuse[ J ]. J Clin Psychiatry,2009,70 ( Suppl2 ) : 10 - 14.
  • 6Weisberg RB. Overview of generalized anxiety disorder:epidemiology, presentation, and course [ J ]. J Clin Psychiatry,2009,70 ( Suppl 2 ) :4 -9.
  • 7Brawman - Mintzer O, Knapp RG, Nietert PJ. Adjunctive risperidone in generalized anxiety disorder: a double - blind, placebo - controlled study[ J]. J Clin Psychiatry,2005,66(10) : 1321 - 1325.
  • 8Pandina GJ ,Canuso CM ,Turkoz 1 ,et al. Adjunctive risperidone in the treatment of generalized anxiety disorder: a double- blind, prospec- tive, placebo - controlled, randomized trim [ J ]. Psychopharmacol Bull,2007,40 ( 3 ) :41 - 57.
  • 9Pollack MH, Simon NM,Zalta AK,et al. Olanzapine augmentation of fluoxetine for refractory generalized anxiety disorder: a placebo con- trolled study [ J ]. Biol Psychiatry ,2006,59 ( 3 ) :211 - 2115.
  • 10Simon NM, Connor KM, LeBeau RT, et al. Quetiapine augmentation of paroxetine CR for the treatment of refractory generalized anxiety dis- order:preliminary findings [ J ]. Psychopharmacology ( Berl ), 2008, 197(4) :675 -678.

共引文献4

同被引文献44

  • 1李洪超,高林竹,董鹏.艾司西酞普兰药物经济学研究综述[J].中国药物经济学,2008,0(2):6-20. 被引量:8
  • 2中华医学会精神科分会.CCMD-3中国精神障碍分类与诊断标准[M].济南:山东科学技术出版社,2001.31-91.
  • 3熊春琴.广泛性焦虑障碍的药物治疗进展探析[J].医药前沿,2012;2(5) :86-7.
  • 4Weisberg RB. Overview of generalized anxiety disorder: epidemiology, presentation, and course [ J ]. J Clin Psychiatry,2009,70(Suppl2) :4 - 9.
  • 5Davidson JR. First-line pharmacotherapy approaches for generalized anxi- ety disorder[ J]. J Clin Psychiatry,2009,70( Suppl 2) :25 - 31.
  • 6Pollack MH. Refractory generalized anxiety disorder[ J]. J Clin Psychi- atry,2009,70(Suppl2) :32 -38.
  • 7Dalrymple KL.Longer term outcomes need to be examined for enhancing the treatment of social anxiety disorder after insufficient improvement with sertraline[J].Evid Based Ment Health,2014,17(2):50.
  • 8Pollack MH,van Ameringen M,Simon NM,et al.A double-blind randomized controlled trial of augmentation and switch strategies for refractory social anxiety disorder[J].Am J Psychiatry,2014,171(1):44.
  • 9de Almeida CA,Brenner CG,Minetto L,et al.Determination of anti-anxiety and anti-epileptic drugs in hospital effluent and a preliminary risk assessment[J].Chemosphere,2013,93(10):2 349.
  • 10Aqababa H,Tabandeh M,Tabatabaei M,et al.Computer-assisted design and synthesis of a highly selective smart adsorbent for extraction of clonazepam from human serum[J].Mater Sci Eng C Mater Biol Appl,2013,33(1):189.

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部